An overview of developing TNF-α targeted therapy for the treatment of psoriasis

Abstract

Introduction: Three biologic drugs targeting TNF-α are approved to treat moderate-to-severe cutaneous psoriasis. These are adalimumab, etanercept and infliximab. These drugs are given by subcutaneous injection or intravenous infusion, and while generally safe and effective, they are expensive with potential for side effects. Thus, numerous new drug candidates are under development that also target TNF-α.

Areas covered: In this review, the authors detail several drugs under development that target TNF-α, focusing on those drugs in preclinical, Phase I and II trials. The authors describe emerging biologic psoriasis therapies, including biosimilars and novel biologics, in addition to several synthetic and naturally derived small-molecule drug candidates.

Expert opinion: The currently approved TNF-α antagonists benefit from over 10 years of safety and efficacy data. The expense and method of administration of these biologics, however, can be cumbersome, and less expensive alternatives have the potential to benefit patients with psoriasis. It is inevitable, despite the introduction of new anti-IL-17 therapies, that established TNF-α targeted therapies, as well as newcomers targeting TNF-α, will continue to play an important role in the lifelong management of psoriasis.

Keywords:

• anti-TNF-α agents
• biosimilar therapies
• curcumin
• psoriasis
• psoriatic arthritis
• targeted therapies

Declaration of interest

C Ryan has acted as advisor, consultant and/or speaker for AbbVie, Eli Lilly and Company, Medimetriks, Pfizer, Inc., and Xenoport. A Menter has been an advisor, consultant and/or speaker for AbbVie, Allergan, Amgen, Inc., Boehringer Ingelheim, Celgene, Convoy Therapeutics, Inc., Eli Lilly and Company, Genentech, Janssen Pharmaceuticals, BioTech, Inc., Leo Pharma, Novartis, Pfizer, Inc., Syntrix, Wyeth and Xenoport. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes

This box summarizes key points contained in the article.